India Serving Great for Clinical Trials, Says Reports!
India Serving Great for Clinical Trials, Says Reports! While the medical industry across globe is taking steps to increase, if we say that India is like winning the candidate in the race. And here is to explain why this is happening. In the recent article by Business standards and many others like PTI, Experts from the pharmaceutical industry say that in the past 10 years, it’s become easier and faster to do clinical trials in India. What do numbers say? Big companies from around the world are starting to choose India as their main place for these trials. From 2017 to 2023, the number of phase two and phase three clinical trials in India has been increasing by about 15 to 18 percent. This growth is mainly because of changes made to a law called the Drugs and Cosmetics Act of 1940. Novartis, one of the biggest pharmaceutical companies globally, talked about this. Why this change has come? India’s regulators are starting to make changes because of what’s happening globally. They’re trying to make the process clearer and quicker. They’re also making a new law that will have big changes, like treating medical devices differently. Role that Hospitals play in the achievement Now that we know numbers, let us discuss about the actual contenders. Who do you think is contributing the most? Is the hospitals responsible in this as well? The answer to this is a BIG FAT YES! No secret right, that the hospital chains and networks are modernizing? Around 70 percent of patients go to private hospital networks. T These networks are expanding into smaller cities and towns, providing access to more patients. This makes India a good place for clinical trials. However, hold on. There are so many experts who think there are still things India needs to improve. Like what? One of the things is doing clinical trials in India is good but somehow challenging. Are there challenges for Pharma? A little yes, given that India is rising. The companies are considering this big trend as they move from asking whether they should be in India to when and how they should enter. They see several opportunities where they can start slowly with one or two important trials in the next year or so and then grow that experience naturally. Dr. Christopher Corsico, a leader at GSK, mentioned that many companies have set up a strong infrastructure in India because of the skilled people there who can help with running clinical trials smoothly. What is the hurdle for the Clinical trials in India? Medical industry is really challenging and we just saw some perspective. There’s also a perception that things used to be slow and burdensome in India for clinical trials. Timelines were tough. Even if you planned to involve India from the beginning, it often took a long time for them to join, and by then, much of the trial was already finished. However, things are changing, and timelines have actually improved by about 30 to 40 percent. Including India early on in global trials can have benefits in the long run, avoiding the need for additional studies later. Conclusion In conclusion, leaders in the pharmaceutical industry see India as an increasingly attractive destination for clinical trials.They say India has gotten better at making it easier to do these experiments, like building better roads for medicine adventures! But, there are still some things they need to work on, like making sure everyone gets fair chances to use new medicines. Even though there are challenges, these big medicine leaders are excited to work together and make things better.
